Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fibrin formation via the coagulation cascade refers to the biochemical process by which blood changes from a liquid to a gel, forming a clot to stop bleeding after vascular injury. It involves a series of enzymatic reactions—comprising the intrinsic, extrinsic, and common pathways—where inactive coagulation factors are sequentially activated, leading to the conversion of fibrinogen to fibrin by thrombin. Fibrin polymers form a mesh that stabilizes the initial platelet plug, achieving hemostasis. This process is essential for wound healing but, when dysregulated, contributes to thrombosis or bleeding disorders. Therapies typically target enzymes in this cascade to prevent or dissolve clots in disease states.
Inhibition of coagulation factors (e.g., thrombin inhibition, factor Xa inhibition); Enhancement of fibrinolysis (e.g., tPA promoting plasmin activity); Prevention of fibrin polymerization
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fibrin formation via coagulation cascade.